The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Hansa Biopharma (Australia) Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
6 result(s) found, displaying 1 to 6
-
Australian Public Assessment Report (AusPAR)Idefirix (imlifidase) has been approved for the desensitisation treatment of highly sensitised adult kidney transplant candidates prior to kidney transplantation
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for IDEFIRIX imlifidase 11 mg powder for concentrate for solution for infusion.
-
Prescription medicine decision summaryTGA decision: Idefirix (imlifidase) has provisional approval for desensitisation treatment of adult kidney transplant candidates.
-
Prescription medicine registrationActive ingredients: imlifidase.
-
Designation or determinationOrphan drug
-
Designation or determinationProvisional determination